Proposals that are incomplete or received after the deadline will not be considered. All ESA Annual Meeting proposal and abstract deadlines are 5:00 PM Eastern so that technical support and ESA staff ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at SLEEP 2026, the 40th annual ...

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous ...

Arbutus Biopharma Corporation announced that five abstracts, including a late-breaker, have been accepted for poster presentations at the EASL Congress 2025 in Amsterdam from May 7 to 10, 2025. The ...

Abstract presenting 48-week IMPACT Phase 2b efficacy and safety data selected for inclusion in “Best of EASL 2026” by EASL Oral presentation will highlight further the 48-week IMPACT efficacy and ...

Incyte (Nasdaq:INCY) today announced that data from key programs in its Hematology and Oncology franchises will be presented at the European Hematology Association (EHA) 2026 Congress, to be held June ...

HANGZHOU and SHAOXING, China, Nov. 13, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces late-breaking abstract poster presentation of interim results from Phase IIb ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that more than 40 abstracts highlighting data from eight of its hematology and oncology products will be presented at the ...

Abstracts that are incomplete or received after the deadline will not be considered. All ESA Annual Meeting proposal and abstract deadlines are 5:00 PM Eastern so that technical support and ESA staff ...